Feasibility and Usability of Intrinsic Capacity Monitoring With Eforto and Its Predictive Value for Health Outcomes in Older Community-dwelling Persons (FORTO 2)
Sponsor: AAL
Listed as NCT05368337, this observational or N/A phase trial focuses on Frailty and remains ongoing. Sponsored by AAL, it has been updated 4 times since 2022, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Unknown
-
Jul 2024 — Sep 2024 [monthly]
Unknown
Status: Unknown Status → Unknown
-
Jun 2024 — Jul 2024 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Jun 2022 — Jun 2024 [monthly]
Not Yet Recruiting
First recorded
May 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AAL
- INNOVIRIS
- Universitair Ziekenhuis Brussel
- Vrije Universiteit Brussel
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.